Defined antinuclear antibodies
For a long time systemic lupus erythematosus (SLE) has been considered to be an autoimmune disease, based on the presence of different kinds of antinuclear antibodies (ANA) in serum samples from patients. Antibodies to double stranded DNA (dsDNA) and Sm are fairly specific for SLE, but other specificities of ANA also occur in other connective tissue diseases (CTD).' More or less convincing associations have been described between the presence of antibodies to La/SS-B and Sjogren's syndrome, and antibodies to Ro/SS-A with neonatal lupus and subacute cutaneous lupus. Data on prevalence and prognostic significance are often controversial, however, probably based on the differences in methodology2 used to measure the ANA and differences in the ethnic composition of the groups of patients studied. Whether ANA actually mediate disease phenomena in CTD is not yet clear, though current data support a role of antibodies to DNA in lupus nephritis and of antibodies to Ro/SS-A in neonatal lupus, congenital heart block, or Sjogren's syndrome. '6 Possible correlations between the presence of different ANA and disease symptoms can be studied from several premises. Most studies investigated the presence of ANA in groups of patients with defined disorders. A second approach is to study the relation between one particular disease manifestation and one specific antinuclear antibody in a defined group of patients. A third would be an epidemiological survey to see whether specific disease symptoms can be observed in groups of patients selected on the basis of one particular antibody present in the serum sample. The latter approach was adopted in this work.
Patients and methods

PATIENTS
From the serum samples sent to our department for routine determination of ANA 37 (14) 8 (22) 3 (8) 4 (11) 2 (5) Cellular casts 15 (6) 5 (33) 1 (7) 1 ( Tan"). Discrepancies have also been obtained and these are generally attributed to the use of different assay systems for the detection of the various ANA, or to the selection of the patients studied.
In the current study, we tried to use detection of the four main specificities of ANA in serum samples sent for the first time to our institute for routine screening of ANA. In this way, no selection regarding clinical syndrome or disease entity is made, yet the detection of autoantibodies is used in the way that it is generally used in a routine setting-that is, without previous knowledge of the disease status of the patient. The method we used for the detection of the specificities ofANA was counterimmunoelectrophoresis, which is still one of the most reliable assays for this purpose, as has been shown by the European Consensus Finding Study Group for detection of ANA (unpublished data). Using this approach and technology we could not confirm many of the relationships published previously.
Antibodies to Ro/SS-A have been described in association with primary Sjogren's syndrome, subacute lupus erythematosus, neonatal lupus erythematosus, lupus erythematosus negative for ANA, and photosensitive rashes.3 ' The putative relation between the presence of antibodies to Ro/SS-A and subacute lupus erythematosus has further been substantiated by case reports of antibodies to Ro/SS-A positive patients who had had Sjogren's syndrome for a prolonged period of time and then suddenly developed the cutaneous lesions of subacute lupus erythematosus.4 In our study, however, in which we started with undefined serum samples, we observed no clear correlation with one or more defined clinical symptoms. We paid special attention to all kinds of skin lesions described in CTD, such as butterfly rash, photosensitive rashes, discoid lesions of the scarring or non-scarring type, alopecia, and scleroderma. Overall, these results sustain the observation that in well defined SLE, no correlations with defined clinical symptoms could be observed.'2 13 We did not study the relevance of differences in titre, which may have been of influence in our results. It has been reported that in SLE there are in fact two subgroups positive for antibodies to Ro/SS-A which differ quantitatively, clinically, and genetically.14 From our data, it may be concluded that doubts can be raised about the use of detection of antibodies to Ro/SS-A as a diagnostic criterion for Sjogren's syndrome. ' In our study, we found a relatively low incidence of antibodies to La/SS-B among the serum samples positive for ANA. The correlation of antibodies to La/SS-B with Sjogren's syndrome was confirmed by this study, however.
Antibodies to Sm are generally considered to be specific for SLE, yet they occur in only about 20% of patients. Discrepancies obtained in the various studies can easily be attributed to (a) racial differences between the groups of patients studied, (b) the selection of patients, and (c) the method used for the detection of antibodies to Sm. Within a well defined population of patients with SLE a positive relation with the occurrence of nephritis'6 and pleuropericarditis'7 next to a negative correlation with the presence of central nervous system disease'8 has been described. These correlations could not be confirmed by others, however. 9 20 In a previous study, we found that antibodies to Sm did not correlate significantly with any particular manifestation of SLE.2 In the present study, we observed an increased incidence of skin lesions such as butterfly rashes and discoid lesions associated with antibodies to Sm. This seems to agree with data presented in an abstract by Powers et al, 2' who described 16 patients with antibodies to Sm as the only autoantibody characterised by these forms of skin lesions.
Antibodies to Sm are often seen in association with antibodies to nRNP. In the 19 serum samples positive for antibodies to Sm, antibodies to nRNP could be detected in 13 patients. These are, however, 16 of the serum samples positive for antibodies to nRNP that do not contain antibodies to Sm.
With respect to antibodies to nRNP, an increased incidence of Raynaud's phenomenon has been reported in patients with SLE containing this specificity for ANA in their serum samples.2>24 Conflicting data have been published about the incidence of other clinical symptoms such as renal disease, central nervous system disease, and myositis in association with antibodies to nRNP. It has been reported that most patients with antibodies to nRNP in their serum samples will satisfy the diagnosis of SLE,25 but no prognostic differences were found between patients positive and patients negative for antibodies to nRNP.22 In this study, the most striking correlation between the presence of antibodies to nRNP and a clinical feature was found for myocarditis.
In conclusion, the clinical relevance of a particular antinuclear antibody can be studied from different starting premises. In most studies, one of the following approaches is applied: (a) patients are selected on the basis of a clinical diagnosis and the incidence of different symptoms is compared with the autoantibodies measured in the serum samples of these patients; or (b) starting from a particular defined clinical symptom, frequencies of autoantibodies in the various patient groups are studied. Using these approaches, several correlations have been obtained between autoantibodies and disease spectra. In our study, we used a third approach, by selecting the patients randomly only on the basis of the presence in serum samples of one of four (antibodies to Ro/SS-A, La/SS-B, Sm, and nRNP) antinuclear antibody specificities. Afterwards, we studied the occurrence of clinical symptoms in the four groups of patients thus obtained. In this way, many of the formerly obtained correlations could not be confirmed. It should be noted that the results can be influenced by the disease duration of the various patients. In patients with SLE the amount of disease symptoms present depends on the disease duration. In this study, however, the start point was having one particular antinuclear antibody and the diagnostic significance was evaluated afterwards. All results must be regarded from the laboratory point of view, when at routine examination a serum sample is positive for one specific antinuclear antibody in this way. Correlations were found between the presence in serum samples of antibodies to Sm and the occurrence of butterfly rashes, discoid lesions, and myocarditis, between antibodies to nRNP and myocarditis, and antibodies to La/SS-B and Sjogren's syndrome.
